Optimal treatment of social phobia: systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
This article proposes a number of recommendations for the treatment of generalized social phobia, based on a systematic literature review and meta-analysis. An optimal treatment regimen would include a combination of medication and psychotherapy, along with an assertive clinical management program. For medications, selective serotonin reuptake inhibitors and dual serotonin-norepinephrine reuptake inhibitors are first-line choices based on their efficacy and tolerability profiles. The nonselective monoamine oxidase inhibitor, phenelzine, may be more potent than these two drug classes, but because of its food and drug interaction liabilities, its use should be restricted to patients not responding to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors. There are other medication classes with demonstrated efficacy in social phobia (benzodiazepines, antipsychotics, alpha-2-delta ligands), but due to limited published clinical trial data and the potential for dependence and withdrawal issues with benzodiazepines, it is unclear how best to incorporate these drugs into treatment regimens. There are very few clinical trials on the use of combined medications. Cognitive behavior therapy appears to be more effective than other evidence-based psychological techniques, and its effects appear to be more enduring than those of pharmacotherapy. There is some evidence, albeit limited to certain drug classes, that the combination of medication and cognitive behavior therapy may be more effective than either strategy used alone. Generalized social phobia is a chronic disorder, and many patients will require long-term support and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801 · cited 1×
“In four studies, response was defined as a 50% reduction in a clinician-rated instrument (eg, Liebowitz Social Anxiety Scale 107 or Hamilton Anxiety Scale 108 ) or, in one case, a self-rated instrument (Fear Questionnaire) 109 .”
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
Magee, W. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020077009 · Cited by 996
Social fears and social phobia in the USA: results from the National Comorbidity survey replication
Ruscio, A. M., Brown, T. A., Chiu, W. T., Sareen, J., Stein, M. B., & Kessler, R. C. (2008) · Psychological Medicine · doi:10.1017/s0033291707001699 · Cited by 835 · cited 1×
“The most commonly reported fears relate to public speaking or speaking up in a meeting or a class.(4) The disorder is associated with Dovepress”
BackgroundCognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561 · cited 2×
“Three studies 95–97 have published follow-up data on outcomes after a treatment-free period.”
BackgroundResultPhenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
The epidemiology of social phobia: Findings from the Duke Epidemiological Catchment Area Study
Davidson, J. R. T., Hughes, D. L., George, L. K., & Blazer, D. G. (1993) · Psychological Medicine · doi:10.1017/s0033291700025484 · Cited by 435 · cited 1×
“9% having attempted suicide.(6,7) The course of social phobia tends to be chronic, with a long duration of illness(8) and low rates of recovery.”
BackgroundFluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415
Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404 · cited 1×
“There are three placebo-controlled RCT, one each for clonazepam,(82) bromazepam,(83) and alprazolam.(53) All studies showed significantly greater improvement on a range of clinician-rating and self-rating scales compared with placebo.”
BackgroundBenzodiazepines, memory and mood: a review
Valerie Curran, H. (1991) · Psychopharmacology · doi:10.1007/bf02316856 · Cited by 401 · cited 1×
“Benzodiazepine use should be limited to brief courses because of their dependence liability, relatively high levels of cognitive toxicity,(102) and potential for interfering with psychological treatment.(103) Low doses of quetiapine are also commonly used for anxiolysis,(104,105) but the one RCT for this drug in socia…”
BackgroundPsychological treatment of social anxiety disorder: a meta-analysis
Acarturk, C., Cuijpers, P., van Straten, A., & de Graaf, R. (2009) · Psychological Medicine · doi:10.1017/s0033291708003590 · Cited by 333 · cited 2×
“38) compared with placebo or treatment as usual.(15,16) In addition to the question of whether psychological treatments are effective, a second question is which psychological treatment is optimal.”
BackgroundKoszycki, D., Benger, M., Shlik, J., & Bradwejn, J. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2007.04.011 · Cited by 321 · cited 1×
“Koszycki et al 90 randomized participants with DSM-IV diagnoses of generalized social phobia to either group CBT or mindfulness-based stress reduction.”
The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress
Ravindran, L. N., & Stein, M. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06218blu · Cited by 317
Hedman, E., Andersson, G., Ljótsson, B., Andersson, E., Rück, C., Mörtberg, E., & Lindefors, N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018001 · Cited by 285 · cited 1×
“The availability of psychological treatments such as CBT is often limited by funding or therapist constraints, so recent RCT that have found Internet CBT to be equally effective as the therapist-delivered version are a promising development.(93,94) More research is required to determine whether Internet therapy can be…”
BackgroundPande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227 · cited 1×
“The anxiolytic dose-response has only been formally assessed for pregabalin, and efficacy is only evident at the maximum dose (600 mg/day), but not at lower doses.(73,74) This is in contrast with the effect of pregabalin in, eg, generalized anxiety disorder, where the anxiolytic dose-response is seen at much lower dos…”
Blanco, C., Heimberg, R. G., Schneier, F. R., Fresco, D. M., Chen, H., Turk, C. L., Vermes, D., Erwin, B. A., Schmidt, A. B., Juster, H. R., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.11 · Cited by 206 · cited 2×
“There are four studies that have assessed treatment response in direct comparisons of psychological treatment with combined medication-psychological treatments in social phobia (two SSRI studies, 33,39 two monoamine oxidase inhibitor studies 98,99 Figure 8).”
BackgroundA Meta–Analytic Review of Psychological Treatments for Social Anxiety Disorder
Powers, M. B., Sigmarsson, S. R., & Emmelkamp, P. M. G. (2008) · International Journal of Cognitive Therapy · doi:10.1521/ijct.2008.1.2.94 · Cited by 191
Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Rüther, E. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601110273 · Cited by 166 · cited 1×
“20,21 The majority of comparative psychotherapy trials do not report responder rates, so a narrative review is provided.”
BackgroundLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Andrews, G., Davies, M., & Titov, N. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.538840 · Cited by 152
Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial
Haug, T. T., Blomhoff, S., Hellstrøm, K., Holme, I., Humble, M., Madsbu, H. P., & Wold, J. E. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.4.312 · Cited by 151 · cited 1×
“Three studies 95–97 have published follow-up data on outcomes after a treatment-free period.”
BackgroundMontgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84 · cited 1×
“43 In these relapse prevention studies, patients were randomized to remain on their SSRI or were switched to placebo, under double-blind conditions.”
BackgroundPharmacotherapy of social phobia
Davidson, J. R. T. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.7.x · Cited by 69
Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder
Hindmarch, I. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02085.x · Cited by 61 · cited 1×
“Benzodiazepine use should be limited to brief courses because of their dependence liability, relatively high levels of cognitive toxicity, 102 and potential for interfering with psychological treatment.”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Antidepressants: Meta-analyses demonstrate that SSRIs and SNRIs are significantly more effective than placebo [58,426-429] and RIMAs [426,428] for the treatment of SAD.”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“However, acute treatment with cognitive therapy (group or individual) is associated with a reduced risk of symptomatic relapse at follow-up [I (M)] (Canton et al., 2012).”
BackgroundSelective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Leichsenring, F., & Leweke, F. (2017) · New England Journal of Medicine · doi:10.1056/nejmcp1614701 · Cited by 256
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
“Two meta-analyses (Blanco et al., 2003; Canton et al., 2012) found stronger evidence of efficacy for the SSRIs than for phenelzine.”
BackgroundResultInfluential
Metadata
- Authors
- Glue, P.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2012-05
- Volume
- 8
- Pages
- 203
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W2055248949
- Cited by
- 105
- References
- 29
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.